Gilteritinib instructions for usage and dosage

Doctors will choose to treat patients with acute myeloid leukemia with Gilteritinib based on the presence of FLT3 mutations in the blood or bone marrow. The recommended starting dose is 120 mg once daily, with or without meals. In the absence of disease progression or unacceptable toxicity, patients are recommended to be treated for at least 6 months to allow time for clinical response. Patients should have their blood counts and blood chemistries, including creatine phosphokinase, assessed at least weekly for the first month, every other week for the second month, and monthly during treatment before starting giritinib. Electrocardiogram (ECG) monitoring is required on days 8 and 15 of cycle 1 and before the start of the next two cycles.